Search for: "Teva Pharmaceuticals" Results 1361 - 1380 of 1,430
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 Nov 2009, 4:51 am
(Class 99) United States US General Wisconsin judge vacates $ 1.26 billion judgment in default against PepsiCo (IPKat) (IP Factor) California Court of Appeal: Von Dutch tradename settlement gives rise to legal malpractice action and questionable mediation confidentiality decision: Michael Cassel v Superior Court of Los Angeles County (The IP ADR Blog) US Patent Reform Putting the USPTO to work for independent inventors (Director's Forum) (Inventive Step) (IP Asset Maximizer Blog) (Patently-O)… [read post]
4 Mar 2024, 9:45 am by Dennis Crouch
Teva Pharmaceuticals USA, Inc. held that in the AIA, Congress did not change the meaning of “on sale” from the pre-AIA statute. [read post]
16 Nov 2009, 4:51 am
(Class 99) United States US General Wisconsin judge vacates $ 1.26 billion judgment in default against PepsiCo (IPKat) (IP Factor) California Court of Appeal: Von Dutch tradename settlement gives rise to legal malpractice action and questionable mediation confidentiality decision: Michael Cassel v Superior Court of Los Angeles County (The IP ADR Blog) US Patent Reform Putting the USPTO to work for independent inventors (Director's Forum) (Inventive Step) (IP Asset Maximizer Blog) (Patently-O)… [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files opposition:… [read post]
9 Aug 2008, 1:50 am
: (Techdirt), Microsoft Research launches new tools for knowledge sharing: (creativecommons.org), Yet another star singer, Duffy, doesn’t mind file-sharing: (Techdirt)   Events 20 August – Bill Patry speaking on copyright – Melbourne: (Patry Copyright Blog), (LawFont.com), 21 August – Bill Patry speaking on copyright – Canberra: (Patry Copyright Blog), (LawFont.com), 22 August – Bill Patry speaking on copyright – Sydney:… [read post]
29 Aug 2008, 1:25 pm
: (IP finance), Facebook removes international access to Scrabulous, except from India: (Ars Technica), (Techdirt), Reverse engineering can resolve conflict between standardisation and competition: (Techdirt), Benefits of piracy aren’t always in the expected places: (Techdirt)   Events 1-3 September: Federation of Indian Chambers of Commerce and Industry, Department of Industrial Property and Promotion, and WIPO conference on ‘Development and IP: Building synergies… [read post]
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan Pharmaceuticals ULC v Eli Lilly Canada… [read post]
26 Sep 2010, 10:08 pm by Marie Louise
Teva Pharmaceuticals USA Inc. et al (Docket Report) District Court N D Illinois: Draft opinion letter sinks induced infringement claim: Goss International Americas, Inc. v. [read post]
13 Dec 2018, 11:16 am by Adam Feldman
Teva Pharmaceuticals USA Inc., which asks: “Whether, under the Leahy-Smith America Invents Act, an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for purposes of determining the patentability of the invention. [read post]
27 Sep 2009, 2:30 pm
Teva and Myland and Dr. [read post]
21 May 2019, 6:18 am by Elizabeth McCuskey
They can be “subsumed within an already tightly circumscribed legal analysis,” as the court recently explained in the patent-construction context in Teva Pharmaceuticals USA Inc. v. [read post]
28 Jan 2010, 9:43 am by Guest Barista
  As explained in the ruling, the story started in the early 1980’s, when some researchers at Alston University in England developed some tetrazine derivatives and, in conjunction with UK pharmaceutical company May & Baker, began testing these for use against various cancers. [read post]
3 Aug 2020, 7:02 am by Elizabeth McAuliffe (Bristows)
Where there are specialists with a focus on the kind of work with which a patent is concerned, they are the relevant addressees of the patent and their specialist skills are attributed to the notional skilled person, even if the patent might also be of a broader application and of interest to non-specialists (Medimmune Ltd v Novartis Pharmaceuticals UK Ltd [2013] RPC 27). [read post]
27 Apr 2023, 9:22 am by Miquel Montañá (Clifford Chance)
For this reason, in its judgment of 25 July 2018 (case C-121/17 Teva UK Ltd and others v Gilead Sciences), it was inevitable that article 69 EPC and the protocol would slip into the judgment: “46. [read post]
7 Dec 2018, 12:58 am by Oswin Ridderbusch
Novartis’ competitor Teva, however, appealed the grant of this SPC before the Appeal Court of Paris on 22 July 2016 and pointed to the formally still existing earlier SPC (FR07C0042) held by Novartis for the same combination product. [read post]
1 Jun 2011, 4:54 pm by Christa Culver
Teva Pharmaceuticals USADocket: 10-1070Issue(s): When a case becomes moot as the result of a third party’s independent action after the court of appeals issues a judgment but while a petition for rehearing is still pending, should the court of appeals vacate the judgment upon the request of the aggrieved party? [read post]